Global

Hereditary Angioedema Treatment & C1-INH

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

C1-INH treatment works by replacing the missing or dysfunctional C1-INH protein in patients with HAE. It can be directly administered to Hereditary Angioedema (HAE) patients to treat acute attacks or as short- and long-term prophylaxis.1

Berinert® is a highly purified human pasteurized nanofiltered C1-INH concentrate, indicated for use in the treatment of acute attacks of Hereditary Angioedema.11

Mechanism of action

Therapeutic C1-INH replaces the actions of natural C1-INH in patients with HAE. This leads to the inhibition of the classical complement cascade, the contact system, the blood clotting cascade and the fibrinolytic system. The result is the prevention of local inflammation by complement and bradykinin (BK).1 12-13 Because of its long half-life (a range 32—47 hours), this effect is sustained over the duration of an HAE attack and minimizes the risk of rebound edema.14-15

The mechanism of action of therapeutic C1-INH, which mimics the action of natural C1-INH.

The mechanism of action of therapeutic C1-INH, which mimics the action of natural C1-INH.

Share
LinkedIn Twitter Facebook Google+